DR. JAMES RICHARD GOLDENRING, MD
Osteopathic Medicine in Nashville, TN
License number
Tennessee 037547
Category
Osteopathic Medicine
Type
General Practice
Address
Address
1310 S Tennessee Vly, Nashville, TN 37212
Phone
(615) 936-3726
Personal information
See more information about JAMES RICHARD GOLDENRING at radaris.comName
Address
Phone
4301 Dakota Ave, Nashville, TN 37209
Nashville, TN
100 Shepards Sq, Nashville, TN 37211
4301 Dakota Ave, Nashville, TN 37209
4833 Redcastle Rdg, Nashville, TN 37211
Professional information
James Goldenring, Nashville TN
Specialties:
Clinical Pharmacology, General Practice, Surgery
Work:
Tennessee Valley Healthcare System
1310 24Th Ave S, Nashville, TN 37212
1310 24Th Ave S, Nashville, TN 37212
Education:
Yale University (1986)
Dr. James R Goldenring, Nashville TN - MD (Doctor of Medicine)
Specialties:
General Surgery
Address:
1310 24Th Ave S, Nashville 37212
(615) 936-3726 (Phone)
(615) 936-3726 (Phone)
Languages:
English
Education:
Medical School
Yale University
Graduated: 1986
Yale University
Graduated: 1986
Screen For Risk For Gastric Adenocarcinoma
US Patent:
6773890, Aug 10, 2004
Filed:
Jan 29, 2002
Appl. No.:
10/060113
Inventors:
James R. Goldenring - Nashville TN
P. Henry Schmidt - Augusta GA
Jeffrey R. Lee - Martinez GA
P. Henry Schmidt - Augusta GA
Jeffrey R. Lee - Martinez GA
Assignee:
Medical College of Georgia Research Institute, Inc. - Augusta GA
International Classification:
G01N 3353
US Classification:
435 71, 435810, 5303871
Abstract:
It has been determined that a specific metaplastic lineage that contains immunoreactivity for a trefoil polypeptide, spasmolytic peptide, is associated with and gives rise to the vast majority of human adenocarcinomas. The identification of this Spasmolytic Polypeptide Expressing Metaplasia (SPEM) is a major factor for grading of biopsies of the stomach to assess risk for gastric cancer. It also forms the basis of a method for serological screening for those at risk for gastric cancer. In a preferred embodiment, antibodies to spasmolytic peptide (hSP) are used in immunostaining of biopsies of gastric tissue obtained by endoscopy for grading biopsies. Those patients having these cells, characterized by a morphology more typical of a type of cell present normally in the intestine and not stomach, Brunners gland cells, are at risk of developing adenocarcinoma. Since these cells express hSP, antibodies or nucleic acid probes hybridizing to mRNA encoding hSP, can be used for rapid detection of the cells in tissue biopsies. The antibodies can also be used in serological tests for screening and following patients at risk for gastric cancer.
James Richard Goldenring, Nashville TN
Specialties:
Family Physician
Address:
1310 24Th Ave S, Nashville, TN 37212
Methods Of Screening For Gastrointestinal Cancer
US Patent:
7811778, Oct 12, 2010
Filed:
Sep 5, 2007
Appl. No.:
11/850555
Inventors:
James R. Goldenring - Nashville TN, US
Assignee:
Vanderbilt University - Nashiville TN
International Classification:
G01N 33/574
US Classification:
435 723, 435 71, 435 6
Abstract:
Methods for diagnosing an upper gastrointestinal (GI) cancer in a subject by determining an amount of one or more biomarkers in a biological sample from the subject are provided. Methods for determining whether to initiate or continue prophylaxis or treatment of an upper GI cancer in a subject by determining any measurable change in the amounts of the at least one biomarker in each of a series of biological samples provided over a time period are also provided.
Methods Of Screening For Gastric Cancer
US Patent:
2011005, Mar 10, 2011
Filed:
Aug 18, 2010
Appl. No.:
12/858846
Inventors:
James R. Goldenring - Nashville TN, US
Ki Taek Nam - Franklin TN, US
Hyuk-Joon Lee - Seoul, KR
Han-Kwang Yang - Seoul, KR
Woo Ho Kim - Seoul, KR
Ki Taek Nam - Franklin TN, US
Hyuk-Joon Lee - Seoul, KR
Han-Kwang Yang - Seoul, KR
Woo Ho Kim - Seoul, KR
International Classification:
C12Q 1/68, G01N 33/574
US Classification:
435 6, 435 71
Abstract:
Method and systems are provided for diagnosing or monitoring a gastric cancer in a subject. Such methods include providing a biological sample from the subject; determining an amount in the sample of at least one biomarker, selected from the group consisting of: CDH17 and OLFM4; and comparing the amount of the at least one biomarker in the sample, if present, to a control level of the at least one biomarker. Such systems include a probe for selectively binding each of at least one biomarker.